Litzow Mark R
Division of Hematology and Blood and Marrow Transplant, Mayo Clinic, 200 1st Street South West, Rochester, MN 55905, USA.
Best Pract Res Clin Haematol. 2018 Dec;31(4):357-360. doi: 10.1016/j.beha.2018.09.004. Epub 2018 Sep 20.
Before the advent of tyrosine kinase inhibitors (TKIs), Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and chemotherapy combination without allo-HSCT, the need for allo-HSCT in Ph+ ALL has become less certain. This review summarizes evidence that will address the relevance of allo-HSCT in Ph+ ALL.
在酪氨酸激酶抑制剂（TKIs）出现之前，费城染色体阳性急性淋巴细胞白血病（Ph+ ALL）患者若不进行异基因造血干细胞移植（allo-HSCT），其生存率极低。最近的证据表明，TKI与化疗联合应用可导致高完全缓解率，从而使更多患者能够进行allo-HSCT。然而，随着越来越多的研究报告称，TKI与化疗联合应用且不进行allo-HSCT也能取得非劣效的结果，Ph+ ALL患者进行allo-HSCT的必要性变得不那么确定了。本综述总结了相关证据，以探讨allo-HSCT在Ph+ ALL中的相关性。
